108 related articles for article (PubMed ID: 16764881)
41. Long-term treatment with nifedipine modulates procoagulant marker and C-C chemokine in hypertensive patients with type 2 diabetes mellitus.
Nomura S; Shouzu A; Omoto S; Nishikawa M; Iwasaka T
Thromb Res; 2005; 115(4):277-85. PubMed ID: 15668187
[TBL] [Abstract][Full Text] [Related]
42. [Effect of yimai jiangya extract on platelet activation and fibrinolytic activity and angiotensin II in aged patients with essential hypertension].
Duan X; Yang D; Sun X
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2000 Jul; 20(7):508-10. PubMed ID: 11789207
[TBL] [Abstract][Full Text] [Related]
43. New marker of platelet activation, SCUBE1, is elevated in hypertensive patients.
Özkan G; Ulusoy S; Menteşe A; Karahan SC; Cansiz M
Am J Hypertens; 2013 Jun; 26(6):748-53. PubMed ID: 23443724
[TBL] [Abstract][Full Text] [Related]
44. Role of angiotensin II in plasma PAI-1 changes induced by imidapril or candesartan in hypertensive patients with metabolic syndrome.
Fogari R; Zoppi A; Mugellini A; Maffioli P; Lazzari P; Derosa G
Hypertens Res; 2011 Dec; 34(12):1321-6. PubMed ID: 21814211
[TBL] [Abstract][Full Text] [Related]
45. Association between the rate of the morning surge in blood pressure and cardiovascular events and stroke.
Luo Y; Wang YL; Wu YB; Xu Y; Head GA; Barry M; Liang YL
Chin Med J (Engl); 2013 Feb; 126(3):510-4. PubMed ID: 23422116
[TBL] [Abstract][Full Text] [Related]
46. Increased levels of tissue plasminogen activator antigen in essential hypertension. A population-based study in Sweden.
Eliasson M; Jansson JH; Nilsson P; Asplund K
J Hypertens; 1997 Apr; 15(4):349-56. PubMed ID: 9211169
[TBL] [Abstract][Full Text] [Related]
47. Eprosartan effect on fibrinolytic/hemostatic variables in arterial hypertension: a comparative study to losartan.
Makris TK; Stavroulakis G; Papadopoulos DP; Krespi P; Hatzizacharias A; Zilidis A; Tsoukala C; Votteas VE
Drugs Exp Clin Res; 2004; 30(3):125-32. PubMed ID: 15366789
[TBL] [Abstract][Full Text] [Related]
48. Fibrinolytic system in normotensive subjects and hypertensive patients.
Armas-Hernández MJ; Hernández-Hernández R; Armas-Padilla MC; Sosa-Canache B; Cammarata R; Pacheco B; Guerrero-Pajuelo J; Israili ZH; Valasco M
Am J Ther; 2007; 14(2):177-82. PubMed ID: 17414587
[TBL] [Abstract][Full Text] [Related]
49. Soluble, platelet-bound, and total P-selectin as indices of platelet activation in congestive heart failure.
Chung I; Choudhury A; Patel J; Lip GY
Ann Med; 2009; 41(1):45-51. PubMed ID: 18618353
[TBL] [Abstract][Full Text] [Related]
50. Mechanism and clinical significance of the prothrombotic state in patients with essential hypertension.
Yang P; Liu YF; Yang L; Wei Q; Zeng H
Clin Cardiol; 2010 Jun; 33(6):E81-6. PubMed ID: 20552613
[TBL] [Abstract][Full Text] [Related]
51. Is the plasminogen activator inhibitor-1 gene a candidate gene predisposing to hypertension? Results from a population-based study in Spain.
Martínez-Calatrava MJ; González-Sánchez JL; Zabena C; Martínez-Larrad MT; Luque-Otero M; Serrano-Ríos M
J Hypertens; 2007 Apr; 25(4):773-7. PubMed ID: 17351368
[TBL] [Abstract][Full Text] [Related]
52. [Increased sP-selectin and other cardiovascular risk factors: fibrinogen, tissue plasminogen activator (t-PA Ag) and acute phase proteins after kidney transplantation].
Kvasnicka J; Viklický O; Umlaufová A; Kvasnicka T; Teplá E; Homolková H; Malíkova I; Sauerová R
Sb Lek; 2002; 103(3):411-7. PubMed ID: 12688185
[TBL] [Abstract][Full Text] [Related]
53. Platelet function and fibrinolytic activity during rest and exercise in borderline hypertensive patients.
Gleerup G; Vind J; Winther K
Eur J Clin Invest; 1995 Apr; 25(4):266-70. PubMed ID: 7601202
[TBL] [Abstract][Full Text] [Related]
54. [Morning rise of systolic blood pressure (by 24-hour ambulatory monitoring) and platelet aggregability in essential hypertension patients].
Oshchepkova EV; Lazareva NV; Filatova LV; Zelveian PA; Arabidze GG
Ter Arkh; 2000; 72(4):47-51. PubMed ID: 10833799
[TBL] [Abstract][Full Text] [Related]
55. Association of blood pressure with fibrinolytic potential in the Framingham offspring population.
Poli KA; Tofler GH; Larson MG; Evans JC; Sutherland PA; Lipinska I; Mittleman MA; Muller JE; D'Agostino RB; Wilson PW; Levy D
Circulation; 2000 Jan; 101(3):264-9. PubMed ID: 10645922
[TBL] [Abstract][Full Text] [Related]
56. [2013 Ambulatory blood pressure monitoring recommendations for the diagnosis of adult hypertension, assessment of cardiovascular and other hypertension-associated risk, and attainment of therapeutic goals (summary). Joint recommendations from the International Society for Chronobiology (ISC), American Association of Medical Chronobiology and Chronotherapeutics (AAMCC), Spanish Society of Applied Chronobiology, Chronotherapy, and Vascular Risk (SECAC), Spanish Society of Atherosclerosis (SEA), and Romanian Society of Internal Medicine (RSIM)].
Hermida RC; Smolensky MH; Ayala DE; Portaluppi F; Crespo JJ; Fabbian F; Haus E; Manfredini R; Mojón A; Moyá A; Piñeiro L; Ríos MT; Otero A; Balan H; Fernández JR
Clin Investig Arterioscler; 2013; 25(2):74-82. PubMed ID: 23849214
[TBL] [Abstract][Full Text] [Related]
57. Effects of severe hypertension on endothelial and platelet microparticles.
Preston RA; Jy W; Jimenez JJ; Mauro LM; Horstman LL; Valle M; Aime G; Ahn YS
Hypertension; 2003 Feb; 41(2):211-7. PubMed ID: 12574084
[TBL] [Abstract][Full Text] [Related]
58. Human platelet activation by thrombolytic agents: effects of tissue-type plasminogen activator and urokinase on platelet surface P-selectin expression.
Kawano K; Aoki I; Aoki N; Homori M; Maki A; Hioki Y; Hasumura Y; Terano A; Arai T; Mizuno H; Ishikawa K
Am Heart J; 1998 Feb; 135(2 Pt 1):268-71. PubMed ID: 9489975
[TBL] [Abstract][Full Text] [Related]
59. A cross-sectional, diurnal, and follow-up study of platelet activation and endothelial dysfunction in malignant phase hypertension.
Lip GY; Edmunds E; Hee FL; Blann AD; Beevers DG
Am J Hypertens; 2001 Aug; 14(8 Pt 1):823-8. PubMed ID: 11497201
[TBL] [Abstract][Full Text] [Related]
60. Elevation of plasminogen activator inhibitor 1 in borderline hypertension is linked to concomitant metabolic disturbances.
Lemne C; De Faire U
Eur J Clin Invest; 1996 Aug; 26(8):692-7. PubMed ID: 8872066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
